Research Overview
What Dihexa is
Dihexa was developed from angiotensin IV, a fragment with reported activity in learning and memory paradigms. Attaching a hexanoic acid group at one end and an aminohexanoic amide at the other produced a compound far more metabolically stable and far more lipophilic than the parent peptide. The literature describes it as a positive modulator of hepatocyte growth factor signalling through the c-Met receptor rather than a direct receptor agonist.
Why a nasal format is used in research
- Olfactory and trigeminal pathways have been described as routes that can deliver molecules toward the CNS without passing through hepatic first-pass metabolism
- A metered pump gives repeatable delivered volume, which matters when the endpoint is exposure rather than potency
- The mucosal surface area and clearance rate are themselves variables that intranasal delivery studies measure
- Solution stability, pH and osmolality of the vehicle influence what fraction of applied material stays available
Research endpoints associated with Dihexa
How this differs from the vial format
The chemistry is identical; what changes is that concentration, vehicle and delivery volume are fixed at fill rather than chosen at the bench. Laboratories needing arbitrary concentrations or non-aqueous systems generally work from the lyophilized powder instead.
